BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 19915614)

  • 1. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
    Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
    Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
    Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1.
    Zhang X; Wu H; Dobson JR; Browne G; Hong D; Akech J; Languino LR; Stein GS; Lian JB
    J Cell Biochem; 2015 Sep; 116(9):2098-108. PubMed ID: 25808168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Runx2 induces bone osteolysis by transcriptional suppression of TSSC1.
    Wang DC; Wang HF; Yuan ZN
    Biochem Biophys Res Commun; 2013 Sep; 438(4):635-9. PubMed ID: 23933319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2.
    Colden M; Dar AA; Saini S; Dahiya PV; Shahryari V; Yamamura S; Tanaka Y; Stein G; Dahiya R; Majid S
    Cell Death Dis; 2017 Jan; 8(1):e2572. PubMed ID: 28125091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
    Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
    J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells.
    Pratap J; Wixted JJ; Gaur T; Zaidi SK; Dobson J; Gokul KD; Hussain S; van Wijnen AJ; Stein JL; Stein GS; Lian JB
    Cancer Res; 2008 Oct; 68(19):7795-802. PubMed ID: 18829534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone.
    Kim B; Kim H; Jung S; Moon A; Noh DY; Lee ZH; Kim HJ; Kim HH
    J Bone Miner Res; 2020 Jan; 35(1):155-166. PubMed ID: 31505052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.
    Mendoza-Villanueva D; Zeef L; Shore P
    Breast Cancer Res; 2011 Oct; 13(5):R106. PubMed ID: 22032690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
    Ganguly SS; Hostetter G; Tang L; Frank SB; Saboda K; Mehra R; Wang L; Li X; Keller ET; Miranti CK
    Oncogene; 2020 Jan; 39(1):204-218. PubMed ID: 31467432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.
    Baniwal SK; Khalid O; Gabet Y; Shah RR; Purcell DJ; Mav D; Kohn-Gabet AE; Shi Y; Coetzee GA; Frenkel B
    Mol Cancer; 2010 Sep; 9():258. PubMed ID: 20863401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion.
    Zhang H; Pan Y; Zheng L; Choe C; Lindgren B; Jensen ED; Westendorf JJ; Cheng L; Huang H
    Cancer Res; 2011 May; 71(9):3257-67. PubMed ID: 21505104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.
    Dey P; Jonsson P; Hartman J; Williams C; Ström A; Gustafsson JÅ
    Mol Endocrinol; 2012 Dec; 26(12):1991-2003. PubMed ID: 23028063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
    Taipaleenmäki H; Browne G; Akech J; Zustin J; van Wijnen AJ; Stein JL; Hesse E; Stein GS; Lian JB
    Cancer Res; 2015 Apr; 75(7):1433-44. PubMed ID: 25634212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
    Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
    PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Runx2-Smad signaling impacts the progression of tumor-induced bone disease.
    Zhang X; Akech J; Browne G; Russell S; Wixted JJ; Stein JL; Stein GS; Lian JB
    Int J Cancer; 2015 Mar; 136(6):1321-32. PubMed ID: 25053011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion.
    Pratap J; Javed A; Languino LR; van Wijnen AJ; Stein JL; Stein GS; Lian JB
    Mol Cell Biol; 2005 Oct; 25(19):8581-91. PubMed ID: 16166639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.